Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Cash from Financing Activities data on file, last reported at $1.3 million in Q4 2025.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $1.3 million in Q4 2025; TTM through Dec 2025 was $101.4 million, a 41.53% increase from a year earlier, with the FY2025 full-year figure at $101.4 million, up 41.53% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $1.3 million, up from $352000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for INBX reached as high as $199.9 million in Q3 2023 and fell as low as $352000.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $53.4 million across 3 years, with a median of $32.9 million in 2024.
• On a YoY basis, Cash from Financing Activities climbed as much as 157.8% in 2025 and fell as far as 157.8% in 2025.
• Year by year, Cash from Financing Activities stood at $860000.0 in 2023, then soared by 3731.4% to $32.9 million in 2024, then tumbled by 96.19% to $1.3 million in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.3 million in Q4 2025, $352000.0 in Q3 2025, and $99.8 million in Q1 2025.